SLC1A2 and Parkinson disease: Although there are limited studies identifying miR‐543 as a dysregulated miRNA in PD, a recent study found that the inhibition of miR‐543‐3p can possibly relieve dyskinesia in a PD model through the rescue of glutamate transporter type 1 (GLT‐1) expression and function [36].